Bladder-Sparing Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer

被引:1
作者
Ericson, Kyle J. [1 ,2 ]
Murthy, Prithvi B. [1 ,2 ]
Bryk, Darren J. [1 ,2 ]
Ramkumar, Rathika R. [1 ,2 ]
Broughman, James R. [1 ]
Khanna, Abhinav [1 ,2 ]
Mian, Omar Y. [1 ,3 ]
Campbell, Steven C. [1 ,2 ]
机构
[1] Cleveland Clin, Cleveland, OH 44106 USA
[2] Glickman Urol & Kidney Inst, Dept Urol, Cleveland, OH USA
[3] Taussig Canc Inst, Dept Radiat Oncol, Cleveland, OH USA
关键词
Bladder cancer; bladder-sparing treatment; nonmetastatic muscle-invasive bladder cancer; radical cystectomy; LONG-TERM OUTCOMES; QUALITY-OF-LIFE; COMBINED-MODALITY THERAPY; SELECTIVE ORGAN PRESERVATION; ASSISTED RADICAL CYSTECTOMY; TRANSURETHRAL RESECTION; NEOADJUVANT CHEMOTHERAPY; UROTHELIAL CARCINOMA; RADIATION-THERAPY; TRIMODAL THERAPY;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Bladder-sparing therapies for the treatment of nonmetastatic muscle-invasive bladder cancers are included in both American and European guidelines. Numerous treatment approaches have been described, including partial cystectomy, radiation monotherapy, and radical transurethral resection. However, the most oncologically favorable and well-studied regimen employs a multimodal approach that consists of maximal transurethral resection of the bladder tumor followed by concurrent radiosensitizing chemotherapy and radiotherapy. This sequence, referred to as trimodal therapy (TMT), has been evaluated with robust retrospective comparative studies and prospective series, although a randomized trial comparing TMT with radical cystectomy has not been performed. Despite promising reports of 5-year overall survival rates of 50% to 70% in well-selected patients, relatively few patients qualify as ideal candidates for TMT. Specifically, contemporary series exclude patients who have clinical stage T3 disease, multifocal tumors, coexisting carcinoma in situ, or hydronephrosis. Herein, we review all forms of bladder-preserving therapies with an emphasis on TMT, highlighting the rationale of each component, survival outcomes, and future directions.
引用
收藏
页码:697 / 707
页数:11
相关论文
共 71 条
  • [61] Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort
    Svatek, Robert S.
    Shariat, Shahrokh F.
    Novara, Giacomo
    Skinner, Eila C.
    Fradet, Yves
    Bastian, Patrick J.
    Kamat, Ashish M.
    Kassouf, Wassim
    Karakiewicz, Pierre I.
    Fritsche, Hans-Martin
    Izawa, Jonathan I.
    Tilki, Derya
    Ficarra, Vincenzo
    Volkmer, Bjoern G.
    Isbarn, Hendrik
    Dinney, Colin P.
    [J]. BJU INTERNATIONAL, 2011, 107 (06) : 898 - 904
  • [62] COMBINED MODALITY PROGRAM WITH POSSIBLE ORGAN PRESERVATION FOR INVASIVE BLADDER-CARCINOMA - RESULTS OF RTOG PROTOCOL 85-12
    TESTER, W
    PORTER, A
    ASBELL, S
    COUGHLIN, C
    HEANEY, J
    KRALL, J
    MARTZ, K
    VENNER, P
    HAMMOND, E
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 25 (05): : 783 - 790
  • [63] Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: Results of Radiation Therapy Oncology Group phase II trial 8802
    Tester, W
    Caplan, R
    Heaney, J
    Venner, P
    Whittington, R
    Byhardt, R
    True, L
    Shipley, W
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) : 119 - 126
  • [64] Tomas DH, 1999, BJU INT, V83, P432
  • [65] Radical Cystectomy Compared to Combined Modality Treatment for Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
    Vashistha, Vishal
    Wang, Hanzhang
    Mazzone, Andrew
    Liss, Michael A.
    Svatek, Robert S.
    Schleicher, Mary
    Kaushik, Dharam
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 97 (05): : 1002 - 1020
  • [66] Wijkström H, 1998, BRIT J UROL, V81, P686
  • [67] Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer
    Williams, Stephen B.
    Shan, Yong
    Jazzar, Usama
    Mehta, Hemalkumar B.
    Baillargeon, Jacques G.
    Huo, Jinhai
    Senagore, Anthony J.
    Orihuela, Eduardo
    Tyler, Douglas S.
    Swanson, Todd A.
    Kamat, Ashish M.
    [J]. JAMA SURGERY, 2018, 153 (10) : 881 - 889
  • [68] Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
    Witjes, J. Alfred
    Lebret, Thierry
    Comperat, Eva M.
    Cowan, Nigel C.
    De Santis, Maria
    Bruins, Harman Maxim
    Hernandez, Virginia
    Espinos, Estefania Linares
    Dunn, James
    Rouanne, Mathieu
    Neuzillet, Yann
    Veskimae, Erik
    van der Heijden, Antoine G.
    Gakis, Georgios
    Ribal, Maria J.
    [J]. EUROPEAN UROLOGY, 2017, 71 (03) : 462 - 475
  • [69] Super Extended Versus Extended Pelvic Lymph Node Dissection in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Comparative Study
    Zehnder, Pascal
    Studer, Urs E.
    Skinner, Eila C.
    Dorin, Ryan P.
    Cai, Jie
    Roth, Beat
    Miranda, Gus
    Birkhaeuser, Frederic
    Stein, John
    Burkhard, Fiona C.
    Daneshmand, Sia
    Thalmann, George N.
    Gill, Inderbir S.
    Skinner, Donald G.
    [J]. JOURNAL OF UROLOGY, 2011, 186 (04) : 1261 - 1268
  • [70] Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: Results of a urodynamic and quality of life study on long-term survivors
    Zietman, AL
    Sacco, D
    Skowronski, U
    Gomery, P
    Kaufman, DS
    Clark, JA
    Talcott, JA
    Shipley, WU
    [J]. JOURNAL OF UROLOGY, 2003, 170 (05) : 1772 - 1776